Timothy C Nichols

List of Publications by Year
in descending order

94	4,789	117625	95266
papers	citations	34 h-index	68 g-index

94	94	94	3153
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Medicine, 1999, 5, 56-63.	30.7	549
2	Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood, 2002, 99, 2670-2676.	1.4	333
3	A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nature Biotechnology, 2021, 39, 47-55.	17.5	238
4	Sustained Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in Liver. Molecular Therapy, 2000, 1, 154-158.	8.2	171
5	Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood, 2005, 105, 3079-3086.	1.4	162
6	Lack of Germline Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vector in Males. Molecular Therapy, 2001, 4, 586-592.	8.2	152
7	Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene Therapy. Human Gene Therapy, 2002, 13, 1281-1291.	2.7	149
8	Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood, 2004, 103, 85-92.	1.4	147
9	Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood, 2005, 105, 3458-3464.	1.4	144
10	Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood, 2010, 116, 5842-5848.	1.4	144
11	Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood, 2012, 119, 3024-3030.	1.4	139
12	Efficacy and Safety of Long-term Prophylaxis in Severe Hemophilia A Dogs Following Liver Gene Therapy Using AAV Vectors. Molecular Therapy, 2011, 19, 442-449.	8.2	116
13	Neonatal or hepatocyte growth factorâ€“potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood, 2003, 101, 3924-3932.	1.4	105
14	Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood, 2010, 115, 4678-4688.	1.4	104
15	Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nature Communications, 2013, 4, 2773.	12.8	102
16	The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12991-12996.	7.1	100
17	The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood, 2012, 120, 4521-4523.	1.4	100
18	NF-kappaB and reperfusion injury. Drug News and Perspectives, 2004, 17, 99.	1.5	98

#	Article	IF	Citations
19	Long-Term Efficacy of Adeno-Associated Virus Serotypes 8 and 9 in Hemophilia A Dogs and Mice. Human Gene Therapy, 2006, 17, 427-439.	2.7	95
20	Targeted Disruption of LDLR Causes Hypercholesterolemia and Atherosclerosis in Yucatan Miniature Pigs. PLoS ONE, 2014, 9, e93457.	2.5	90
21	Role of Nuclear Factor-Kappa B (NF-Î¹B) in Inflammation, Periodontitis, and Atherogenesis. , 2001, 6, 20-29.		81
22	Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood, 2009, 113, 3682-3689.	1.4	79
23	A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood, 2003, 102, 2403-2411.	1.4	76
24	Sustained Phenotypic Correction of Canine Hemophilia B After Systemic Administration of Helper-Dependent Adenoviral Vector. Human Gene Therapy, 2005, 16, 811-820.	2.7	74
25	Protein Replacement Therapy and Gene Transfer in Canine Models of Hemophilia A, Hemophilia B, von Willebrand Disease, and Factor VII Deficiency. ILAR Journal, 2009, 50, 144-167.	1.8	71
26	Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6080-6085.	7.1	68
27	Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs. Molecular Therapy, 2010, 18, 1318-1329.	8.2	66
28	Non-invasive inÂVivo Characterization of Human Carotid Plaques with Acoustic Radiation Force Impulse Ultrasound: Comparison with Histology after Endarterectomy. Ultrasound in Medicine and Biology, 2015, 41, 685-697.	1.5	66
29	Animal Models of Hemophilia. Progress in Molecular Biology and Translational Science, 2012, 105, 151-209.	1.7	62
30	Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood, 2005, 105, 145-152.	1.4	59
31	Recombinant canine B-domainâ€“deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Blood, 2009, 114, 4562-4565.	1.4	55
32	Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce. Molecular Therapy, 2017, 25, 512-522.	8.2	54
33	Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood, 2003, 102, 4393-4398.	1.4	40
34	Failure to Achieve Gene Conversion with Chimeric Circular Oligonucleotides: Potentially Misleading PCR Artifacts Observed. Oligonucleotides, 1998, 8, 531-536.	4.3	38
35	Magnetic and Contrast Properties of Labeled Platelets for Magnetomotive Optical Coherence Tomography. Biophysical Journal, 2010, 99, 2374-2383.	0.5	38
36	Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. Thrombosis Research, 2007, 120, 269-280.	1.7	35

#	Article	IF	Citations
37	Animal Models of Hemophilia and Related Bleeding Disorders. Seminars in Hematology, 2013, 50, 175-184.	3.4	34
38	Von Willebrand Factor and Animal Models: Contributions to Gene Therapy, Thrombotic Thrombocytopenic Purpura, and Coronary Artery Thrombosis. Mayo Clinic Proceedings, 1991, 66, 733-742.	3.0	33
39	Blood outgrowth endothelial cell migration and trapping in vivo: a window into gene therapy. Translational Research, 2009, 153, 179-189.	5.0	32
40	Thrombotic Thrombocytopenia Induced in Dogs and Pigs. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 793-800.	2.4	30
41	Translational Data from Adeno-Associated Virus-Mediated Gene Therapy of Hemophilia B in Dogs. Human Gene Therapy Clinical Development, 2015, 26, 5-14.	3.1	29
42	SPLENIC CLEARANCE MECHANISMS OF REHYDRATED, LYOPHILIZED PLATELETS. Artificial Cells, Blood Substitutes, and Biotechnology, 2001, 29, 439-451.	0.9	28
43	An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Molecular Therapy - Methods and Clinical Development, 2018, 10, 257-267.	4.1	28
44	Thrombus Formation with Rehydrated, Lyophilized Platelets. Hematology, 2002, 7, 359-369.	1.5	27
45	Influence of diabetes on the foreign body response to nitric oxide-releasing implants. Biomaterials, 2018, 157, 76-85.	11.4	26
46	Coronary Artery Disease Risk-Associated Plpp3 Gene and Its Product Lipid Phosphate Phosphatase 3 Regulate Experimental Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2261-2272.	2.4	26
47	Performance of acoustic radiation force impulse ultrasound imaging for carotid plaque characterization with histologic validation. Journal of Vascular Surgery, 2017, 66, 1749-1757.e3.	1.1	25
48	Intracellular function in rehydrated lyophilized platelets. British Journal of Haematology, 2000, 111, 167-174.	2.5	25
49	Porcine and Canine von Willebrand Factor and von Willebrand Disease: Hemostasis, Thrombosis, and Atherosclerosis Studies. Thrombosis, 2010, 2010, 1-11.	1.4	22
50	Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. Blood Advances, 2018, 2, 505-508.	5.2	21
51	ExÂVivo Porcine Arterial and Chorioallantoic Membrane Acoustic Angiography Using Dual-Frequency Intravascular Ultrasound Probes. Ultrasound in Medicine and Biology, 2016, 42, 2294-2307.	1.5	20
52	Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity. Molecular Therapy - Methods and Clinical Development, 2020, 18, 259-268.	4.1	20
53	Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII. Blood, 2016, 127, 565-571.	1.4	19
54	Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models. Journal of Translational Medicine, 2017, 15, 94.	4.4	16

#	Article	IF	Citations
55	von Willebrand Factor Does Not Influence Atherogenesis in Arteries Subjected to Altered Shear Stress. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 323-330.	2.4	13
56	Superior human hepatocyte transduction with adeno-associated virus vector serotype 7. Gene Therapy, 2019, 26, 504-514.	4.5	13
57	Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants. Blood Advances, 2021, 5, 1324-1332.	5.2	12
58	Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet. PLoS ONE, 2015, 10, e0132302.	2.5	10
59	Portal Vein Delivery of Viral Vectors for Gene Therapy for Hemophilia. Methods in Molecular Biology, 2014, 1114, 413-426.	0.9	10
60	Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa. PLoS ONE, 2020, 15, e0240896.	2.5	9
61	The interaction of factor VIIa with rehydrated, lyophilized platelets. Platelets, 2008, 19, 182-191.	2.3	8
62	Experimental Validation of ARFI Surveillance of Subcutaneous Hemorrhage (ASSH) Using Calibrated Infusions in a Tissue-Mimicking Model and Dogs. Ultrasonic Imaging, 2016, 38, 346-358.	2.6	6
63	Combination of Nitric Oxide Release and Surface Texture for Mitigating the Foreign Body Response. ACS Biomaterials Science and Engineering, 2021, 7, 2444-2452.	5.2	6
64	A Novel Method of Regional Intravenous Delivery of AAV Vector to Skeletal Muscle Results in Correction of Canine Hemophilia B Phenotype.. Blood, 2004, 104, 3179-3179.	1.4	5
65	Dexamethasone Transiently Enhances Transgene Expression in the Liver When Administered at Late-Phase Post Long-Term Adeno-Associated Virus Transduction. Human Gene Therapy, 2022, 33, 119-130.	2.7	5
66	Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs. Thrombosis and Haemostasis, 2001, 85, 445-9.	3.4	5
67	Intracellular function in rehydrated lyophilized platelets. British Journal of Haematology, 2000, 111, 167-174.	2.5	4
68	Soy Phosphatidylinositolâ€“Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domainâ€“Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs. Journal of Pharmaceutical Sciences, 2016, 105, 2459-2464.	3.3	4
69	Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test â€“ Demonstrated in vitro and ex vivo. PLoS ONE, 2017, 12, e0175030.	2.5	3
70	Severe Hemophilia A in a Male Old English Sheep Dog with a Câ†'T Transition that Created a Premature Stop Codon in Factor VIII. Comparative Medicine, 2016, 66, 405-411.	1.0	3
71	Comparison of multiple beam sequences in arterial ARFI imaging, ex vivo. , 2008, , .		1
72	Reflected shear wave imaging of atherosclerosis. , 2009, , .		1

#	Article	IF	Citations
73	In vivo ARFI surveillance of subcutaneous hemorrhage (ASSH) for monitoring rcFVIII dose response in hemophilia A dogs. , 2014, , .		1
74	In vivo characterization of atherosclerotic plaque of human carotid arteries with histopathological correlation using ARFI ultrasound. , 2014, , .		1
75	DDAVP-Induced Increase of Factor VIII Activity in Blood Is Likely Due To Release of Factor VIII That Is Synthesized by Endothelial Cells.. Blood, 2004, 104, 692-692.	1.4	1
76	De Novo Synthesis & Storage of Human Factor VIII In Platelets Reduces Bleeding In Canine Hemophilia A. Blood, 2010, 116, 2198-2198.	1.4	1
77	ISOLATION AND CHARACTERIZATION OF BIORESPONSIVE RENAL CELLS FROM HUMAN AND LARGE MAMMAL WITH CHRONIC RENAL FAILURE. FASEB Journal, 2009, 23, LB143.	0.5	1
78	Hemophilia A Dogs Tolerant to Human Factor VIII Provide a Unique Model to Determine Efficacy and Safety of AAV Delivery of Novel Factor VIII Variants. Blood, 2019, 134, 3628-3628.	1.4	1
79	FVIII Protein Is Not Detectable in Human PBMCs or Livers from Dogs with an Intron-22 Inversion Mutation: Implications for FVIII Immunogenicity and Tolerance. Blood, 2019, 134, 630-630.	1.4	1
80	Lessons Learned from Animal Models of Inherited Bleeding Disorders. Hematology Education, 2014, 8, 39-46.	0.0	1
81	Specific Correction of the Intron-22 Inverted Factor VIII Gene in Autologous Blood Outgrowth Endothelial Cells from Patients with Severe Hemophilia A. Blood, 2020, 136, 30-31.	1.4	1
82	Chimeric Mice Engrafted With Canine Hepatocytes Exhibits Similar AAV Transduction Efficiency to Hemophilia B Dog. Frontiers in Pharmacology, 2022, 13, 815317.	3.5	1
83	ARFI ultrasound for in vivo monitoring of soft-tissue bleeding and hemostasis in a dog model of hemophilia. , 2010, , .		0
84	In vivo detection of hemorrhage rate in dog models of hemophilia and VWD and at human femoral arteriotomy by ARFI ultrasound. , 2011, , .		0
85	Gene Transfer to Macrophages with Nanoparticle-Loaded Platelets.. Blood, 2005, 106, 3043-3043.	1.4	0
86	Use of Engineered Autologous BOEC for Gene Therapy of Canine Hemophilia A.. Blood, 2005, 106, 1281-1281.	1.4	0
87	Interaction of Recombinant Factor VIIa with Rehydrated, Lyophilized Platelets.. Blood, 2005, 106, 3994-3994.	1.4	0
88	Long-Term Efficacy of Adeno-associated Virus Serotypes 8 and 9 in Hemophilia A Dogs and Mice. Human Gene Therapy, 2006, .	2.7	0
89	Long Term Dose-Dependent Correction of Hemophilia A Dogs Using AAV-8 and AAV-9-Mediated FVIII Gene Transfer.. Blood, 2006, 108, 999-999.	1.4	0
90	Recombinant Human IL-11 (rhIL-11, NeumegaÂ®) Increases VWF Activity in Type 1 Von Willebrand Disease.. Blood, 2006, 108, 1003-1003.	1.4	0

#	Article	IF	Citations
91	Successful and Safe Treatment of Canine Hemophilia by Continuous Expression of Canine FVIIa: a Model for FVIII/FIX Gene-Based Bypassing Agents. Blood, 2008, 112, lba-4-lba-4.	1.4	0
92	Phase II Biologic Effects Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Moderate or Mild Hemophilia A or Von Willebrand Disease Unable to Use DDAVP,. Blood, 2011, 118, 3308-3308.	1.4	0
93	Generation of a Unique Cohort of Hemophilia A Dogs Tolerant to Human FVIII for Evaluating the Safety and Efficacy of AAV Delivery of Wild Type and Variant Human FVIII. Blood, 2018, 132, 2453-2453.	1.4	0
94	Ontogeny of the Alloimmune Anti-Canine Factor VIII Inhibitor Response in Severe Hemophilia Î‘ Dogs. Blood, 2021, 138, 3173-3173.	1.4	0